Therapeutics News and Research

RSS

Arrowhead increases ownership in Calando's outstanding equity to 79%

Arrowhead Research Corporation today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Arrowhead now owns approximately 79% of Calando's outstanding equity.

19 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.

18 Jan 2011

Study finds miRNAs inhibits prostate cancer metastasis

A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine.

18 Jan 2011

Health Canada requests Osiris for additional information in support of Prochymal approval

Osiris Therapeutics, Inc. today announced that Health Canada has requested additional information in support of the Company's application for approval of Prochymal, a stem cell therapy, for the treatment of graft vs. host disease (GvHD).

14 Jan 2011

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer.

14 Jan 2011

Vanderbilt, Scripps Research form partnership to open new institute

The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.

14 Jan 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

13 Jan 2011

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

A Blanchette Rockefeller Neurosciences Institute study published today in the Journal of Neuroscience reveals underlying causes for the degeneration of synapses in Alzheimer's Disease and identifies promising pharmaceutical solutions for the devastating condition that affects more than 5 million people in the United States.

12 Jan 2011

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive results from Inovio's multi-antigen Chikungunya virus (CHIKV) DNA vaccine in PLoS Neglected Tropical Diseases.

12 Jan 2011

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

A Blanchette Rockefeller Neurosciences Institute (BRNI) study published today in the Journal of Neuroscience reveals underlying causes for the degeneration of synapses in Alzheimer's Disease and identifies promising pharmaceutical solutions for the devastating condition that affects more than 5 million people in the United States.

12 Jan 2011

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

The Scripps Research Institute and the University of Pennsylvania School of Medicine have been awarded approximately $8.2 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of tobacco addiction. Of the funds awarded, $5.7 million will go to Scripps Research, and $2.5 million to the University of Pennsylvania.

12 Jan 2011

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

AstraZeneca and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

12 Jan 2011

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.

11 Jan 2011

Scientists create particles that resemble RBC, pave way for development of synthetic blood

A team of scientists has created particles that closely mirror some of the key properties of red blood cells, potentially helping pave the way for the development of synthetic blood.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Therapeutics News and Research

Arrowhead increases ownership in Calando's outstanding equity to 79%

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Study finds miRNAs inhibits prostate cancer metastasis

Health Canada requests Osiris for additional information in support of Prochymal approval

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Vanderbilt, Scripps Research form partnership to open new institute

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

Scientists create particles that resemble RBC, pave way for development of synthetic blood

QIAGEN to acquire minority stake in Alacris Theranostics

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News